Our study investigated whether the TNAP inhibitor SBI-425, PPi and the combination of SBI-425 + PPi was able to prevent the development of arterial media calcification in a rat model of CKD without aggravating bone metabolism. Here, ALPL is linked to chronic kidney disease.